β-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations

Autor: Sanni, SJ, Hansen, JT, Bonde, MM, Speerschneider, T, Christensen, GL, Munk, S, Gammeltoft, S, Hansen, JL

The angiotensin II type 1 (AT(1)) receptor belongs to family A of 7 transmembrane (7TM) receptors. The receptor has important roles in the cardiovascular system and is commonly used as a drug target in cardiovascular diseases. Interaction of 7TM rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4202fa5c9db39230f793cb22a9d436f1
https://europepmc.org/articles/PMC2962824/

GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly.

Autor: Jensen MH; Antag Therapeutics Aps, Copenhagen, Denmark.; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Gasbjerg LS; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Skov-Jeppesen K; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Jacobsen JCB; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Poulsen SS; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Zhou C; Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA., Jakubauskaite R; Department of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Poulsen FR; Department of Neurosurgery, Odense University Hospital, Odense, Denmark., Bonde C; Department of Neurosurgery, Odense University Hospital, Odense, Denmark., Albarazi M; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark., Halle B; Department of Neurosurgery, Odense University Hospital, Odense, Denmark., Christiansen CB; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Sanni SJ; Antag Therapeutics Aps, Copenhagen, Denmark., Byberg S; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Hoe B; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark., Holst JJ; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark., Dela F; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Human Physiology and Biochemistry, Riga Stradiņš University, Riga, Latvia., Rasmussen AK; Department of Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Knop FK; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Arlien-Søborg MC; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark., Melmed S; Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA., Jørgensen JOL; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark., Andersen MS; Department of Endocrinology, Odense University Hospital, Odense, Denmark., Hartmann B; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Klose MC; Department of Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Feldt-Rasmussen U; Department of Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Sparre-Ulrich AH; Antag Therapeutics Aps, Copenhagen, Denmark., Rosenkilde MM; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Aug 22. Date of Electronic Publication: 2024 Aug 22.

[Sar1, Ile4, Ile8]-angiotensin II Potentiates Insulin Receptor Signalling and Glycogen Synthesis in Hepatocytes.

Autor: Sanni SJ; Obesity Biology, Novo Nordisk A/S, Maalov, Denmark.; Department of Clinical Biochemistry, Glostrup Research Institute, Glostrup Hospital, Glostrup, Denmark., Lyngsø C; Department of Clinical Biochemistry, Glostrup Research Institute, Glostrup Hospital, Glostrup, Denmark., Gammeltoft S; Department of Clinical Biochemistry, Glostrup Research Institute, Glostrup Hospital, Glostrup, Denmark., Hansen JL; Diabetes and Cardiovascular Disease, Novo Nordisk A/S, Maalov, Denmark.

Publikováno v: Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2018 May; Vol. 122 (5), pp. 460-469. Date of Electronic Publication: 2017 Dec 15.

Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signaling.

Autor: Bellot M; Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France., Galandrin S; Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France., Boularan C; Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France., Matthies HJ; 1] Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [2] Neuroscience Program in Substance Abuse, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Despas F; 1] Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France. [2] Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Toulouse, Faculté de Médecine, Toulouse, France., Denis C; Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France., Javitch J; 1] Center for Molecular Recognition and Departments of Psychiatry and Pharmacology, Columbia University, New York, New York, USA. [2] College of Physicians and Surgeons, Columbia University, New York, New York, USA. [3] Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, USA., Mazères S; Institut de Pharmacologie et de Biologie Structurale (IPBS), CNRS, UMR 508, Université Toulouse III Paul Sabatier, Toulouse, France., Sanni SJ; 1] Department of Clinical Biochemistry, Glostrup Hospital, Glostrup, Denmark. [2] Diabetes Biology and Metabolism, Novo Nordisk, Måløv, Denmark., Pons V; Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France., Seguelas MH; Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France., Hansen JL; Diabetes Biology and Metabolism, Novo Nordisk, Måløv, Denmark., Pathak A; 1] Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France. [2] Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Toulouse, Faculté de Médecine, Toulouse, France., Galli A; 1] Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [2] Neuroscience Program in Substance Abuse, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [3] Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [4] Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Sénard JM; 1] Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France. [2] Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Toulouse, Faculté de Médecine, Toulouse, France., Galés C; Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, U1048, Université Toulouse III Paul Sabatier, Toulouse, France.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2015 Apr; Vol. 11 (4), pp. 271-9. Date of Electronic Publication: 2015 Feb 23.

Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms.

Autor: Bonde MM; Laboratory for Molecular Cardiology, The Danish National Research Foundation Centre for Cardiac Arrhythmia, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, and The Danish National Research Foundation Centre for Cardiac Arrhythmia, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark., Hansen JT, Sanni SJ, Haunsø S, Gammeltoft S, Lyngsø C, Hansen JL

Publikováno v: PloS one [PLoS One] 2010 Nov 30; Vol. 5 (11), pp. e14135. Date of Electronic Publication: 2010 Nov 30.